Frequency, diagnosis and management of fungal respiratory infections

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 3, 2013, Pages 259-265

  Hayes, Gemma E ^a   Denning, David W ^b  

^a DERRIFORD HOSPITAL   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aspergillus; Pneumocystis; Transplantation

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; FUNGUS ANTIBODY; IMMUNOGLOBULIN G; MICAFUNGIN; VORICONAZOLE;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ANTIBIOTIC RESISTANCE; ANTIFUNGAL RESISTANCE; ASPERGILLOMA; ASPERGILLUS FUMIGATUS; BRONCHIECTASIS; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CRYPTOCOCCUS; DISEASE TRANSMISSION; EARLY DIAGNOSIS; ENDEMIC DISEASE; EUROPE; FUNGAL COLONIZATION; FUNGUS CULTURE; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LABORATORY DEVICE; LUNG ASPERGILLOSIS; LUNG FIBROSIS; LUNG SARCOIDOSIS; LUNG TRANSPLANTATION; LUNG TUBERCULOSIS; MORBIDITY; MORTALITY; PATIENT CARE; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PREVALENCE; PULMONARY CRYPTOCOCCOSIS; REVIEW; SEROLOGY; SUDDEN INFANT DEATH SYNDROME;

ANTIFUNGAL AGENTS; ANTIGENS, FUNGAL; AZOLES; CRYPTOCOCCOSIS; DRUG RESISTANCE; HUMANS; LUNG DISEASES, FUNGAL; PNEUMONIA, PNEUMOCYSTIS; PULMONARY ASPERGILLOSIS; RESPIRATORY TRACT INFECTIONS;

EID: 84878109177     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32835f1ad1     Document Type: Review

References (43)

1. Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis as a sequel to tuberculosis. Bull WHO 2011; 89:864-872.
2. Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J 2012. [Epub ahead of print]
3. Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis in adults with asthma and its complication chronic pulmonary aspergillosis. Med Mycol 2012. [Epub ahead of print]
4. Nam HS, Jeon K, Um SW, et al. Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: a review of 43 cases. Int J Infect Dis 2010; 14:e479-e482.
5. Ohba H, Miwa S, Shirai M, et al. Clinical characteristics and prognosis of chronic pulmonary aspergillosis. Respir Med 2012; 106:724-729.
6. Anandan C, Gupta R, Simpson CR, et al. Epidemiology and disease burden from allergic disease in Scotland: analyses of national databases. J R Soc Med 2009; 102:431-442.
7. Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, healthcare use, and mortality: United States, 2005-2009. Natl Health Stat Report 2011; 12:1- 14.
8. Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 2012; 25:297-317.
9. Choukri F, Menotti J, Sarfati C, et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis 2010; 51:259-265.
10. Le Gal S, Damiani C, Rouillé A, et al. A cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin Infect Dis 2012; 54:e62-e71.
11. Sassi M, Ripamonti C, Mueller NJ, et al. Outbreaks of Pneumocystis pneumonia in two renal transplant centers linked to a single strain of Pneumocystis: implications for transmission and virulence. Clin Infect Dis 2012; 54:1437- 1444.
12. Hauser PM, Bille J, Lass-Flörl C, et al. Multicenter, prospective clinical evaluation of respiratory samples from subjects at risk for Pneumocystis jirovecii infection by use of a commercial real-time PCR assay. J Clin Microbiol 2011; 49:1872-1878.
13. Vargas SL, Ponce CA, Gallo M, et al. Near-universal prevalence of Pneumocystis and associated increase in mucus in the lungs of infants with sudden unexpected death. Clin Infect Dis 2013; 56:171-179.
14. Sivam S, Sciurba FC, Lucht LA, et al. Distribution of Pneumocystis jirovecii in lungs from colonized COPD patients. Diagn Microbiol Infect Dis 2011; 71:24-28.
15. Harris JR, Lindsley MD, Henchaichon S, et al. High prevalence of cryptococcal infection among HIV-infected patients hospitalized with pneumonia in Thailand. Clin Infect Dis 2012; 54:e43-e50.
16. Jarvis JN, Percival A, Bauman S, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIVassociated cryptococcal meningitis. Clin Infect Dis 2011; 53:1019-1023.
17. Lindsley MD, Mekha N, Baggett HC, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 2011; 53:321-325.
18. Qu Y, Liu G, Ghimire P, et al. Primary pulmonary cryptococcosis: evaluation of CT characteristics in 26 immunocompetent Chinese patients. Acta Radiol 2012; 53:668-674.
19. Lengerova M, Kocmanova I, Racil Z, et al. Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-b-D-glucan detection. J Clin Microbiol 2012; 50:602-608.
20. Denning DW, Park S, Lass-Florl C, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52:1123-1129.
21. Torelli R, Sanguinetti M, Moody A, et al. Diagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay. J Clin Microbiol 2011; 49:4273-4278.
22. Reinwald M, Spiess B, Heinz WJ, et al. Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicentre prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol 2012; 89:120-127.
23. D'Haese J, Theunissen K, Vermeulen E, et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol 2012; 50:1258- 1263.
24. de Mol M, de Jongste JC, van Westreenen M, et al. Diagnosis of invasive pulmonary aspergillosis in children with bronchoalveolar lavage galactomannan. Pediatr Pulmonol 2012. [Epub ahead of print]
25. He H, Ding L, Sun B, et al. Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study. Crit Care 2012; 16:R138.
26. Baxter CG, Jones AM, Webb K, Denning DW. Homogenisation of cystic fibrosis sputum by sonication: an essential step for Aspergillus PCR. J Microbiol Methods 2011; 85:75-81.
27. Reinwald M, Hummel M, Kovalevskaya E, et al. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. J Antimicrob Chemother 2012; 67:2260-2267.
28. Thornton C, Johnson G, Agrawal S. Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology. J Vis Exp 2012; 22:pii:3721. doi:10.3791/3721.
29. Wiederhold NP, Najvar LK, Bocanegra R, et al. Interlaboratory and interstudy reproducibility of a novel lateral-flow device and influence of antifungal therapy on the detection of invasive pulmonary aspergillosis. J Clin Microbiol 2013; 51:459-465.
30. Hoenigl M, Koidl C, Duettman W, et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. J Infect 2012; 65:588-591.
31. Blot SI, Taccone FS, Van den Abeele AM, et al. A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med 2012; 186:56-64.
32. Kohno S, Izumikawa K, Ogawa K, et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 2010; 61:410-418.
33. Cadranel J, Philippe B, Hennequin C, et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol Infect Dis 2012; 31:3231-3239.
34. Saito T, Fujiuchi S, Tao Y, et al. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan. Infection 2012; 40:661-667.
35. Kohno S, Izumikawa K, Yoshida M, et al. A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis 2012. [Epub ahead of print]
36. Perfect JR. The impact of the host on fungal infections. Am J Med 2012; 125:S39-S51.
37. Koo S, Kubiak DW, Issa NC, et al. A targeted peritransplant antifungal strategy for the prevention of invasive fungal disease after lung transplantation: a sequential cohort analysis. Transplantation 2012; 94:281-286.
38. Howard SJ, Arendrup MC. Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol 2011; 49 (Suppl 1): S90-S95.
39. Van der Linden JW, Snelders E, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands 2007-2009. Emerg Infect Dis 2011; 17:1846-1854.
40. Mortensen KL, Jensen RH, Johansen HK, et al. Aspergillus species and other moulds in respiratory samples from patients with cystic fibrosis: a laboratorybased study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol 2011; 49:2243-2251.
41. Morio F, Aubin GG, Danner-Boucher I, et al. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother 2012; 67:1870-1873.
42. Burgel PR, Baixench MT, Amsellem M, et al. High prevalence of azoleresistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 2012; 56:869-874.
43. Spiess B, Seifarth W, Merker N, et al. Development of novel PCR assays to detect azole resistance-mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients. Antimicrob Agents Chemother 2012; 56:3905-3910.